Effects of chronic treprostinil treatment on experimental right heart hypertrophy and failure

Cardiology in the Young

Volumn 27, Issue 1, 2017, Pages 90-100

  Axelgaard, Sofie ^a   Holmboe, Sarah ^a   Ringgaard, Steffen ^a   Hillgaard, Thomas K ^a   Andersen, Stine ^a   Hansen, Mona S ^a   Andersen, Asger ^a   Nielsen Kudsk, Jens E ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

prostacyclin; pulmonary hypertension; Right ventricular dysfunction

Indexed keywords

ATRIAL NATRIURETIC FACTOR; COLLAGEN TYPE 1; MESSENGER RNA; MYOSIN HEAVY CHAIN BETA; TREPROSTINIL; ANTIHYPERTENSIVE AGENT; PROSTACYCLIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAPILLARY DENSITY; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE SEVERITY; DOWN REGULATION; DRUG MECHANISM; GENE EXPRESSION REGULATION; HEART DILATATION; HEART HEMODYNAMICS; HEART LEFT VENTRICLE OVERLOAD; HEART RIGHT VENTRICLE FAILURE; HEART RIGHT VENTRICLE HYPERTROPHY; HEART WEIGHT; LONG TERM CARE; MALE; NONHUMAN; RAT; SYSTOLIC BLOOD PRESSURE; TRICUSPID VALVE REGURGITATION; WISTAR RAT; ANALOGS AND DERIVATIVES; ANIMAL; COMPLICATION; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; HEART FAILURE; HEART RIGHT VENTRICLE FUNCTION; HYPERTROPHY, RIGHT VENTRICULAR; PATHOPHYSIOLOGY; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; ANTIHYPERTENSIVE AGENTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EPOPROSTENOL; HEART FAILURE; HYPERTROPHY, RIGHT VENTRICULAR; INFUSIONS, SUBCUTANEOUS; MALE; RATS; RATS, WISTAR; VENTRICULAR FUNCTION, RIGHT;

EID: 84964329162     PISSN: 10479511     EISSN: 14671107     Source Type: Journal    
DOI: 10.1017/S1047951116000160     Document Type: Article

References (28)

1. van Wolferen SA, Marcus JT, Boonstra A, et al. Prognostic value of right ventricular mass, volume and function in idiopathic pulmonary arterial hypertension. Eur Heart J 2007; 28: 1250-1257.
2. Chin KM, Kim NHS, Rubin LJ. The right ventricle in pulmonary hypertension. Coron Artery Dis 2005; 16: 13-18.
3. Sandoval J, Bauerle O, Palomar A, et al. Survival in primary pulmonary hypertension. Validation of a prognostic equation. Circulation 1994; 89: 1733-1744.
4. Apostolakis D, Konstantinides D. The right ventricle in health and disease: insights into physiology, pathophysiology and diagnostic management. Cardiology 2012; 121: 263-273.
5. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010; 122: 156-163.
6. van der Bom T, Winter MM, Bouma BJ, et al. The effect of valsartan on the systemic right ventricular function: a double-blind randomized placebo-controlled pilot trial. Circulation 2013; 127: 322-330.
7. Galié N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009; 34: 1219-1263.
8. Waxman AB, Zamanian RT. Pulmonary arterial hypertension: new insights into the optimal role of current and emerging prostacyclin therapies. Am J Cardiol 2013; 111(Suppl): 1A-16A; quiz 17A-19A.
9. Schermuly RT, Kreisselmeier KP, Ghofrani HA, et al. Anti-remodeling effects of iloprost and the dual-selective phosphodies-terase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension. Circ Res 2004; 94: 1101-1108.
10. Holmboe S, Andersen A, Vildbrad MD, Nielsen JM, Ringgaard S, Nielsen-Kudsk JE. Iloprost improves ventricular function in the hypertrophic and functionally impaired right heart by direct stimulation. Pulm Circ 2013; 3: 870-879.
11. Andersen S, Schultz JG, Andersen A, et al. Effects of bisoprolol and losartan treatment in the hypertrophic and failing right heart. J Card Fail 2014; 20: 864-873.
12. Schou UK, Peters CD, Wan Kim S, Frokiaer J, Nielsen S. Characterization of a rat model of right-sided heart failure induced by pulmonary trunk banding. J Exp Anim Sci 2007; 43: 237-254.
13. Andersen A, Nielsen JM, Peters CD, Schou UK, Sloth E, Nielsen-Kudsk JE. Effects of phosphodiesterase-5-inhibition by sildenafil in the pressure overloaded right heart. Eur J Heart Fail 2008; 10: 1158-1165.
14. Andersen A, Nielsen JM, Holmboe S, Vildbrad MD, Nielsen-Kudsk JE. The effects of cyclic guanylate cyclase stimulation on right ventricular hypertrophy and failure alone and in combination with phosphodiesterase-5 inhibition. J Cardiovasc Pharmacol 2013; 62: 167-173.
15. Ghio S, Recusani F, Klersy C, et al. Prognostic usefulness of the tricuspid annular plane systolic excursion in patients with congestive heart failure secondary to idiopathic or ischemic dilated cardiomyopathy. Am J Cardiol 2000; 85: 837-842.
16. Haddad F, Ashley E, Michelakis ED. New insights for the diagnosis and management of right ventricular failure, from molecular imaging to targeted right ventricular therapy. Curr Opin Cardiol 2010; 25: 131-140.
17. Bogaard HJ. The right ventricle under pressure. Chest 2009; 135: 794-804.
18. Lowes BD, Minobe W, Abraham WT, et al. Changes in gene expression in the intact human heart. Downregulation of alpha-myosin heavy chain in hypertrophied, failing ventricular myocardium. J Clin Invest 1997; 100: 2315-2324.
19. Sano M, Minamino T, Toko H, et al. p53-Induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature 2007; 446: 444-448.
20. Nagaya N, Nishikimi T, Uematsu M, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. J Cardiol 2001; 37: 110-111.
21. van Albada ME, van Veghel R, Cromme-Dijkhuis AH, Schoemaker RG, Berger RM. Treprostinil in advanced experimental pulmonary hypertension: beneficial outcome without reversed pulmonary vascular remodeling. J Cardiovasc Pharmacol 2006; 48: 249-254.
22. Gomez-Arroyo J, Sakagami M, Syed AA, et al. Iloprost reverses established fibrosis in experimental right ventricular failure. Eur Respir J 2015; 45: 449-462.
23. Orie NN, Ledwozyw A, Williams DJ, Whittle BJ, Clapp LH. Differential actions of the prostacyclin analogues treprostinil and iloprost and the selexipag metabolite, MRE-269 (ACT-333679) in rat small pulmonary arteries and veins. Prostaglandins Other Lipid Mediat 2013; 106: 1-7.
24. Clapp LH, Finney P, Turcato S, Tran S, Rubin LJ, Tinker A. Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery. Am J Respir Cell Mol Biol 2002; 26: 194-201.
25. Gomberg-Maitland M, Tapson VF, Benza RL, et al. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. Am J Respir Crit Care Med 2005; 172: 1586-1589.
26. van Albada ME, Berger RM, Niggebrugge M, van Veghel R, Cromme-Dijkhuis AH, Schoemaker RG. Prostacyclin therapy increases right ventricular capillarisation in a model for flow-associated pulmonary hypertension. Eur J Pharmacol 2006; 549: 107-116.
27. Pettersen E, Helle-Valle T, Edvardsen T, et al. Contraction pattern of the systemic right ventricle shift from longitudinal to circumferential shortening and absent global ventricular torsion. J Am Coll Cardiol 2007; 49: 2450-2456.
28. Fontana M, Olschewski H, Olschewski A, Schlüter KD. Trepros-tinil potentiates the positive inotropic effect of catecholamines in adult rat ventricular cardiomyocytes. Br J Pharmacol 2007; 151: 779-786.